Pliant Therapeutics Funding & Investors
South San Francisco, CA
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
pliantrx.comTotal Amount Raised: $694,945,152
Pliant Therapeutics Funding Rounds
Post Ipo Equity
$287,500,000
Post Ipo Equity
$200,000,000
Series C
$100,445,146
Series C Investors
NovartisFarallon Capital ManagementRedmile GroupSurveyor CapitalMenlo VenturesCowenS-Cubed CapitalSchroder AdveqEventideLogos CapitalCormorant Asset ManagementAgent CapitalIPO
Unknown
Series B
$62,000,000
Series B Investors
CowenEventideSchroder AdveqAgent CapitalMenlo VenturesS-Cubed CapitalSeries A
$45,000,000
Series A Investors
Third Rock VenturespH Pharma